Financials BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
156.2 USD -7.00% Intraday chart for BeiGene, Ltd. -8.69% -13.41%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,134 23,494 27,843 22,843 18,862 17,561 - -
Enterprise Value (EV) 1 9,392 19,361 24,097 19,511 16,564 15,975 16,540 16,157
P/E ratio -10.5 x -13.5 x -17.8 x -11.3 x -21.3 x -18.6 x -43.1 x 82 x
Yield - - - - - - - -
Capitalization / Revenue 23.7 x 76.1 x 23.7 x 16.1 x 7.67 x 5.45 x 4.36 x 3.47 x
EV / Revenue 21.9 x 62.7 x 20.5 x 13.8 x 6.74 x 4.96 x 4.11 x 3.2 x
EV / EBITDA -9.98 x -11.9 x -17.3 x -11.3 x -14.8 x -20.4 x -57 x 42.3 x
EV / FCF -11.2 x -13.8 x -15.4 x -10.7 x -9.63 x -20.3 x -40 x 45.5 x
FCF Yield -8.94% -7.24% -6.48% -9.34% -10.4% -4.92% -2.5% 2.2%
Price to Book 11.2 x 5.57 x 4.03 x 5.17 x 5.32 x 6.23 x 6.63 x 5.23 x
Nbr of stocks (in thousands) 61,136 90,924 102,770 103,859 104,578 104,579 - -
Reference price 2 165.8 258.4 270.9 219.9 180.4 167.9 167.9 167.9
Announcement Date 3/2/20 2/25/21 2/25/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 428.2 308.9 1,176 1,416 2,459 3,220 4,027 5,055
EBITDA 1 -941.3 -1,626 -1,392 -1,723 -1,120 -782.7 -290.2 381.6
EBIT 1 -959.9 -1,658 -1,439 -1,790 -1,208 -958.3 -448.7 245.2
Operating Margin -224.16% -536.69% -122.31% -126.4% -49.12% -29.76% -11.14% 4.85%
Earnings before Tax (EBT) 1 -943.6 -1,618 -1,439 -1,961 -825.8 -857.4 -383.2 302.8
Net income 1 -948.6 -1,597 -1,413 -2,004 -881.7 -868.9 -359.9 218.5
Net margin -221.53% -517.01% -120.15% -141.52% -35.86% -26.98% -8.94% 4.32%
EPS 2 -15.80 -19.13 -15.23 -19.43 -8.450 -9.017 -3.899 2.048
Free Cash Flow 1 -839.9 -1,401 -1,562 -1,822 -1,719 -786.3 -413.6 354.7
FCF margin -196.14% -453.57% -132.76% -128.68% -69.93% -24.42% -10.27% 7.02%
FCF Conversion (EBITDA) - - - - - - - 92.94%
FCF Conversion (Net income) - - - - - - - 162.31%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 2/25/21 2/25/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 214 420.4 306.6 341.6 387.6 380.1 606.4 447.8 595.3 1,043 781.3 634.4 751.7 783.2 860 861.2 798 961.6
EBITDA 1 -558.6 - -426.7 -423.9 -422.2 -450.6 - -351.2 - - -112.5 -565.3 -236.1 -225.9 -222.4 -214.2 -115.2 -85.78
EBIT 1 -571.7 - -443.3 -439.4 -438.4 -468.6 -907 -371.3 -318.7 -690 -134 -589.1 -261.3 -248.6 -237.6 -240.7 -169.9 -116.6
Operating Margin -267.19% - -144.57% -128.64% -113.09% -123.29% -149.56% -82.91% -53.54% -66.15% -17.15% -92.86% -34.77% -31.75% -27.63% -27.95% -21.29% -12.12%
Earnings before Tax (EBT) 1 -586.8 - -421.2 -557.6 -551.2 -431 -982.2 -336.9 -367.5 -704.4 229.3 -350.8 -243.4 -258.7 -237.6 -225.7 -185.1 -107.9
Net income 1 -585.7 -999.5 -434.3 -571.4 -557.6 -445.3 -998.1 -348.4 -381.1 -729.6 215.4 -367.6 -251.2 -255.8 -234.8 -222.1 -185.1 -107.9
Net margin -273.7% -237.74% -141.63% -167.3% -143.84% -117.16% -164.59% -77.81% -64.03% -69.94% 27.57% -57.94% -33.41% -32.66% -27.31% -25.79% -23.2% -11.22%
EPS 2 -6.160 - -4.240 -5.560 -5.390 -4.290 - -3.340 -3.640 - 2.010 -3.480 -2.410 -2.453 -2.248 -2.121 -1.810 -1.050
Dividend per Share 2 - - - - - - - - - - - - - - - - - -
Announcement Date 2/25/22 2/25/22 5/5/22 8/4/22 11/9/22 2/27/23 2/27/23 5/4/23 8/2/23 8/2/23 11/9/23 2/26/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 742 4,132 3,746 3,332 2,297 1,586 1,021 1,404
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -840 -1,401 -1,562 -1,822 -1,719 -786 -414 355
ROE (net income / shareholders' equity) -70.2% -66.1% -28% -38.1% -22.3% -26.7% -12.4% 12.3%
ROA (Net income/ Total Assets) -49.1% -44.3% -19.8% -26.9% -14.5% -17.5% -8.35% 6.18%
Assets 1 1,931 3,607 7,123 7,457 6,093 4,959 4,308 3,538
Book Value Per Share 2 14.80 46.40 67.30 42.50 33.90 27.00 25.30 32.10
Cash Flow per Share 2 -12.50 -15.40 -14.00 -14.50 -11.10 -5.300 -1.900 5.300
Capex 1 89.6 118 263 325 562 264 250 273
Capex / Sales 20.93% 38.04% 22.35% 22.98% 22.85% 8.2% 6.22% 5.41%
Announcement Date 3/2/20 2/25/21 2/25/22 2/27/23 2/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
167.9 USD
Average target price
267 USD
Spread / Average Target
+59.01%
Consensus
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. Financials BeiGene, Ltd.